Best Grants for Global Health in New Mexico

The National Cancer Institute (NCI) seeks to enhance the validation of biomarkers and assays for cancer detection and treatment through its UH3 funding mechanism. This initiative supports multi-disciplinary collaborations to validate existing assays over three years using clinical trial specimens. Emphasis is placed on harmonizing laboratory tests and validating pharmacodynamic markers. Projects should not focus on early-stage technology development but aim for integration into clinical studies as investigational assays.

The Washington Tree Fruit Research Commission is inviting research proposals aimed at apple crop protection, emphasizing organic practices and pollinator protection. Key areas of focus include the management of pests like Codling Moth and Fire Blight, testing new crop protection products, enhancing soil health, and developing efficient monitoring techniques. Collaboration among institutions is encouraged, and projects should aim for practical industry applications to ensure sustainable and profitable tree fruit production.

About Pfizer Grants

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Biochemical and Molecular Characterization of Marstacimab and TFPI Pathways 

This competitive grant encompasses research aimed at elucidating molecular and cellular mechanisms underlying marstacimab-TFPI interactions, including but not limited to differential expression of tissue factor and TFPI in various tissues, binding kinetics, and other biochemical properties. Projects should seek to advance foundational understanding of these interactions through innovative approaches in biochemistry, molecular biology, and related disciplines.

Project Types and Area of Interest

Projects that will be considered for Pfizer support will focus on basic science and fundamental biological understanding of Tissue Factor Pathway Inhibitor (TFPI), anti-TFPI Monoclonal Antibodies, and marstacimab. The areas of interest may include (but are not limited to):

• Basic biology of TFPI including interactions among key regulatory proteins in the intrinsic and/or extrinsic clotting cascades (e.g. Protein S being a co-factor for both Protein C and TFPI).
• Impact of differential TFPI expression within tissues and the role of various TFPI pools/isoforms in the regulation of coagulation.
• Pharmacology resulting from concomitant therapies added to anti-TFPI

Accreditation Sustainability Learning Community RFA

The Association of State and Territorial Health Officials (ASTHO), through the Public Health Infrastructure Grant (PHIG), is currently accepting applications for participation in a learning lab that will foster health department capacity to build a sustainable public health accreditation culture within their agencies. This opportunity is open to applicants from direct PHIG awardees at the state-, big city-, and county-level.

The Whole Foods Market Store Giving Program supports local communities by providing financial assistance to 501(c)(3) nonprofit organizations that focus on food access and environmental stewardship. This biannual program allows eligible organizations to apply via the Community Engagement Portal, although not all requests can be fulfilled due to high demand. Priority is given to those without recent funding, promoting sustainable community engagement.

The NIMH Career Transition Award (K22) supports tenure-track intramural investigators at NIMH in their transition to independent research faculty positions. This program aims to foster innovative research in mental health, encouraging applicants with a strong record of research excellence. Key deadlines for applications vary, including those for standard and renewal submissions, emphasizing the importance of timely applications to secure funding and advance mental health research initiatives.

This initiative aims to support research interventions targeting disparities in liver diseases and liver cancer among underserved populations in the U.S. It encourages innovative approaches to reduce health inequities and improve health outcomes. The funding opportunity is available through various deadlines for both standard and renewal applications, promoting multi-level strategies to address these critical health issues effectively.

Susan G Komen Breast Cancer Foundation

The mission of Susan G. Komen® is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer.

Susan G. Komen Career Catalyst Research (CCR) Grants

Susan G. Komen Career Catalyst Research (CCR) Grants foster promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of “protected time” for research career development under the guidance of a Mentor Committee. We seek to support those who will emerge as the next key leaders in the fight against breast cancer.

CCR Research Focus: Research projects must be hypothesis-driven, breast cancer-focused studies. They may be considered basic, translational, clinical and/or population science in nature and should align with Komen’s research priorities and mission to save lives from breast cancer. 

The NCAA Jim McKay Graduate Scholarship honors the legacy of journalist Jim McKay by awarding a one-time $10,000 scholarship to one male and one female student-athlete annually. Eligible candidates must have a minimum GPA of 3.5, demonstrate integrity, and show interest in sports communication. There is no limit to the number of nominations from institutions, highlighting the NCAA's commitment to supporting student-athletes in their academic and professional pursuits.

The NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33) invites research proposals for early phase clinical trials of natural products, including botanicals and dietary supplements, emphasizing scientific validity for further testing. Applicants may receive up to three years of funding for pharmacokinetics and bioavailability studies, with potential for an additional three years to evaluate clinical outcomes. This initiative aims to optimize natural product delivery through innovative study designs.

The NCCIH Natural Product Early Phase Clinical Trial Award supports innovative clinical trials of natural products, such as botanicals and dietary supplements, with a strong scientific basis. Applications are encouraged to explore optimal delivery methods and combinations with other treatments. Funding is available for up to three years to assess the impact on target engagement and clinical outcomes, aiming to translate basic science findings into practical clinical applications.

The NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) grant invites applications for mid-phase clinical trials focusing on natural products such as botanicals and dietary supplements. It aims to advance scientific knowledge by determining optimal dosing and patient responses. Applicants must provide preliminary data demonstrating bioavailability and measurable impacts on target engagement. This initiative will not support efficacy trials for cancer treatments and encourages early contact with NCCIH scientific contacts.

The NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22) aims to support postdoctoral fellows from underrepresented backgrounds in transitioning to tenure-track positions. This award provides essential funding for salary and research support for three years, enabling candidates to establish independent biomedical careers. Key deadlines for applications range from February 2025 to October 2027, ensuring ample opportunity for eligible researchers to secure funding for their career development.

The NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) aims to support innovative research in behavioral and social interventions for dental, oral, and craniofacial conditions. This funding opportunity includes a milestone-driven planning phase of up to 2 years, with potential transition to implementation for an additional 5 years, facilitating comprehensive trial development and assessment.

The DoW Bone Marrow Failure Idea Development Award supports innovative, high-impact research aimed at understanding and curing bone marrow failure diseases. This grant is available to both Established Investigators and Early-Career Investigators, with no preliminary data required for applications. Reviewers assess proposals based on specific criteria tailored to the investigator's career stage. The focus is on achieving interpretable results that contribute significantly to the field.

The DoW Bone Marrow Failure Investigator-Initiated Research Award supports innovative research aimed at advancing the understanding and treatment of bone marrow failure. This funding opportunity encourages applications for translational and clinical studies, requiring preliminary data to strengthen proposals. Unique features include the ability for a partnering Principal Investigator to contribute to the research, thereby fostering collaboration while maintaining a focus on significant advancements in patient care.

The FY26 Bone Marrow Failure Research Program's Resource Development Award aims to create a multiomic atlas from human bone marrow failure samples. This resource will be open-access, providing essential data for researchers and clinicians to enhance their understanding of bone marrow failure diseases. A comprehensive Data Resource Sharing Plan is required to ensure timely availability of the developed resource, fostering collaboration within the scientific community.

The FY26 Parkinson’s Research Program Investigator-Initiated Research Award supports innovative, multidisciplinary research projects aimed at advancing the understanding and treatment of Parkinson’s disease. The award encourages collaboration among multiple principal investigators, requiring preliminary data and allowing clinical trials to enhance research outcomes. This initiative is vital for fostering impactful discoveries within the four specified focus areas of the program, ultimately improving patient care and management.

The FY26 Parkinson’s Research Program (PRP) Early Investigator Research Award supports early-career researchers in Parkinson’s disease (PD) research. It offers two funding levels: Level 1 for fellows requiring a Mentor and Level 2 for independent investigators. The PI must show potential in PD research, with Level 1 emphasizing mentorship and Level 2 needing preliminary data. Research must align with one of the four FY26 PRP Focus Areas, excluding clinical trials.

The SETAC North America Student Meeting Attendance Grant supports student participation in annual meetings, emphasizing inclusivity and excellence. This program provides waived registration and stipends for costs such as travel and dependent care. Eligible students can apply during abstract submission from March to May, with grants available for each degree program. The initiative encourages applicants from diverse backgrounds, particularly those from indigenous communities and minority-serving institutions, enhancing representation within the environmental sciences.

The W. Storrs Cole Memorial Research Award, offered by the Geological Society of America (GSA), supports innovative research in invertebrate micropaleontology. This prestigious award honors the legacy of Dr. W. Storrs Cole, a pivotal figure in the society's history. Recipients may be previous awardees and must have published significant works in the field. The GSA aims to advance geoscience through such initiatives, fostering scientific discovery and professional growth among earth scientists globally.

The DOW Combat Readiness – Medical Research Program's FY26 Translational Research Award supports innovative research aimed at improving trauma care outcomes. This program emphasizes hypothesis-driven studies that can transition promising technologies into practical solutions for enhancing casualty survivability. Applicants must provide preliminary data and utilize validated animal models, with a focus on projects that meet a minimum technology readiness level of 4, ensuring a mature translational research effort.

The NEI Postbaccalaureate Opportunities in Vision Science (POVS) Research Education Program aims to enhance the training of a diverse workforce in biomedical research. This NIH-funded initiative focuses on providing intensive, hands-on research experiences for recent college graduates from various backgrounds, preparing them for doctoral programs in biomedical fields. The program encourages participation from individuals without prior research opportunities in vision sciences, fostering a nationally recruited cohort for substantial impact in the field.

The National Institute of Allergy and Infectious Diseases (NIAID) is advancing research on immune tolerance through its Collaborative Network. This program aims to clarify the mechanisms of immune tolerance and develop interventions for related diseases, including transplant rejection and autoimmune disorders. Key objectives include conducting clinical trials on tolerogenic strategies and refining immune assays. This initiative is supported by regulations under the Public Health Service Act, ensuring a structured approach to improving patient outcomes.

The Translational Transplantation Tolerance Cooperative Study Group, supported by the National Institute of Allergy and Infectious Diseases, aims to advance transplant tolerance strategies that promote long-term graft survival without lifelong immunosuppression. This initiative focuses on developing, optimizing, and evaluating methods to induce immune tolerance in allogeneic transplants through collaborative efforts across multiple centers, utilizing translationally relevant models to ensure effective outcomes.

This grant aims to enhance applied regulatory science research for the evaluation and treatment of cardiotoxicity associated with oncology therapeutics. The initiative will facilitate collaboration with the FDA to develop effective methodologies and solutions, ensuring that research outcomes are directly relevant to regulatory decision-making. Key activities include regular communication with funded investigators and a focus on improving detection and management of cardiotoxicity, ultimately leading to impactful publications and presentations.

The NIH StrokeNet initiative invites applications for clinical trials and biomarker studies aimed at stroke treatment, recovery, and prevention. This funding opportunity encourages collaborative projects that validate promising interventions and scientific aims within the NIH StrokeNet framework. Key deadlines for submissions span from February 2025 to November 2026, with support provided by the National Coordinating Center and Regional Coordinating Centers to ensure efficient study implementation and participant recruitment.